-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|November 5, 2024

Integrating VMS Treatment Into Comprehensive Women’s Health Management

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, JoAnn V. Pinkerton, MD, FACOG, MSCP , Alexa N. Fiffick, DO, MBS, MSCP

Key Takeaways

Hormone therapy for VMS requires careful evaluation of risks, especially in women with pre-existing conditions.
Non-hormonal treatments and lifestyle modifications are vital in managing menopause-related symptoms.
Regular monitoring of bone density and cardiovascular health is essential for comprehensive care.
Personalized treatment plans should consider individual risk factors and patient preferences for optimal management.

SHOW MORE

Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with menopause, such as cardiovascular disease and osteoporosis.

Episodes in this series

EP. 1 Understanding the Burden of Menopausal Vasomotor Symptoms

EP. 1 Understanding the Burden of Menopausal Vasomotor Symptoms

EP. 2 Barriers to VMS Treatment and Impact on Long-Term Health

EP. 2 Barriers to VMS Treatment and Impact on Long-Term Health

EP. 3 Improving Access and Equity in VMS Treatment

EP. 3 Improving Access and Equity in VMS Treatment

EP. 4 Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP. 4 Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP. 5 Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP. 5 Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP. 6 Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP. 6 Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP. 7 Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP. 7 Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP. 8 Safety Profiles of Neurokinin-Targeted Therapies for VMS

EP. 8 Safety Profiles of Neurokinin-Targeted Therapies for VMS

EP. 9 Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP. 9 Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP. 10 Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

EP. 10 Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

Video content above is prompted by the following:

(FIFFICK) Considering the significant comorbidities often associated with menopause, such as cardiovascular disease and osteoporosis, how should VMS treatment be integrated into a broader health management plan for women?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

FDA Panel Backs 6 Peptides for Compounding

Philadelphia Employer Coalition Podcast Targets GLP-1s, Cancer Care

Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD